Alle Storys
Folgen
Keine Story von Deutsche Effecten- und Wechsel-Beteiligungsges. AG mehr verpassen.

Deutsche Effecten- und Wechsel-Beteiligungsges. AG

EANS-News: DEWB Investment Holding NOXXON Pharma AG Achieves Milestone in Partnership with Eli Lilly and Company

Jena/Berlin, Germany, December 3, 2009 (euro adhoc) -

  Corporate news transmitted by euro adhoc. The issuer/originator is solely
  responsible for the content of this announcement.
Company Information
NOXXON Pharma
AG (NOXXON), the biopharmaceutical company focusing on the 
development of novel medicines based on its unique proprietary 
Spiegelmer® technology, announced today the achievement of an 
important milestone in its drug discovery and development partnership
with Eli Lilly and Company (NYSE:LLY).  NOXXON´s successful 
identification of a Spiegelmer® with picomolar affinity and high 
selectivity for its target met contractually specified milestone 
criteria and triggers a payment of an undisclosed amount.  Lilly and 
NOXXON entered into the agreement last year to discover and develop 
Spiegelmers® for the treatment of migraine.
NOXXON´s Chief Scientific Officer, Dr. Sven Klussmann, commented: 
"The rapid delivery of what appears to be an immensely potent 
compound illustrates the power of the Spiegelmer® platform and 
represents the first major landmark in our partnership.  We now look 
forward to Lilly applying its substantial expertise in the field of 
migraine in taking the Spiegelmer® to the next level."
William Chin, M.D., vice president of discovery and clinical research
at Lilly, added: "NOXXON´s identification of the lead compound is an 
outstanding milestone achievement. The use of Spiegelmers® for the 
potential treatment of migraine headache is a novel and promising 
approach. We are excited to continue our work with NOXXON to bring 
Spiegelmers® to our patients as soon as possible." Following the 
completion of the discovery work, the identified Spiegelmer® will 
undergo pharmacological testing and pre-clinical development. Lilly 
is responsible for the pre-clinical and clinical development as well 
as the commercialization of the Spiegelmer® product, provided the 
product is approved by regulatory authorities.
About Spiegelmers® Spiegelmers® (L-aptamers) are chemical entities 
based on synthetic mirror-image oligonucleotides which are highly 
selective for their pharmacological target and potent inhibitors of 
target function. They combine the benefits of small molecule drugs 
and biopharmaceuticals. Due to their unique mirror image 
configuration Spiegelmers® are not metabolized and do not hybridize 
with native nucleic acids. Unlike conventional nucleic acids, 
Spiegelmers® do not activate the innate immune response via toll-like
receptors and they showed an exceptionally favorable immunogenicity 
profile in pre-clinical testing.
About NOXXON Berlin-based NOXXON Pharma AG is a clinical stage 
biotechnology company focusing on the development of Spiegelmers® for
the treatment of inflammatory diseases and hematological indications.
NOXXON is in possession of a broad patent estate and has access to a 
readily scalable GMP production. In addition to its in-house 
programs, NOXXON discovers and develops Spiegelmers® in collaboration
with partners from the pharmaceutical industry, including Lilly, 
Hoffmann La-Roche, and Pfizer. The business strategy of NOXXON is to 
broaden this range of collaborations through co-development and 
licensing agreements for the proprietary clinical and pre-clinical 
products as well as technology-based multi-target partnerships. 
Currently the company has two compounds in clinical development. The 
declared goal of NOXXON is to establish its oligonucleotide-based 
drug discovery platform (Spiegelmers®) as the leading 'scaffold' 
technology to create new chemical entities with superior properties. 
NOXXON´s investors are TVM Capital, Sofinnova Partners, Edmond de 
Rothschild Investment Partners, Deutsche Effecten- und 
Wechsel-Beteiligungsgesellschaft (DEWB), Seventure Partners, Dow 
Venture Capital, Dieckell Group, FCP OP MEDICAL BioHealth-Trends, IBG
Risikokapitalfonds, VC Fonds Berlin, and others.
Website: http://www.noxxon.com
General contact:
Emmanuelle Delabre
NOXXON Pharma AG
Max-Dohrn-Strasse 8-10
10589 Berlin, Germany
Phone: + 49-30-726247-100
FAX: + 49-30-726247-225
Email:  edelabre@noxxon.com
end of announcement                               euro adhoc

Further inquiry note:

Marco Scheidler
Tel.: +49 (0) 3641 573-3600
E-Mail: marco.scheidler@dewb-vc.com

Branche: Financial & Business Services
ISIN: DE0008041005
WKN: 804100
Index: CDAX, Classic All Share, Prime All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Stuttgart / free trade
München / free trade

Weitere Storys: Deutsche Effecten- und Wechsel-Beteiligungsges. AG
Weitere Storys: Deutsche Effecten- und Wechsel-Beteiligungsges. AG